The Fort Worth Press - SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

USD -
AED 3.672497
AFN 65.502706
ALL 80.979656
AMD 377.215764
ANG 1.79008
AOA 916.99964
ARS 1404.011801
AUD 1.406351
AWG 1.8025
AZN 1.702932
BAM 1.643792
BBD 2.01512
BDT 122.389289
BGN 1.67937
BHD 0.376967
BIF 2965.35987
BMD 1
BND 1.266678
BOB 6.913941
BRL 5.178902
BSD 1.0005
BTN 90.584735
BWP 13.12568
BYN 2.874337
BYR 19600
BZD 2.012178
CAD 1.354285
CDF 2209.999697
CHF 0.766905
CLF 0.021642
CLP 854.569689
CNY 6.91085
CNH 6.91007
COP 3665.79
CRC 495.12315
CUC 1
CUP 26.5
CVE 92.677576
CZK 20.36795
DJF 178.163649
DKK 6.274825
DOP 62.707755
DZD 129.429029
EGP 46.8715
ERN 15
ETB 155.312845
EUR 0.83997
FJD 2.18585
FKP 0.731875
GBP 0.730589
GEL 2.690494
GGP 0.731875
GHS 11.010531
GIP 0.731875
GMD 73.499639
GNF 8782.951828
GTQ 7.672912
GYD 209.326172
HKD 7.81681
HNL 26.438786
HRK 6.327399
HTG 131.239993
HUF 318.446503
IDR 16784
ILS 3.078798
IMP 0.731875
INR 90.70785
IQD 1310.634936
IRR 42125.000158
ISK 121.970211
JEP 0.731875
JMD 156.538256
JOD 0.709001
JPY 153.579499
KES 129.000133
KGS 87.450037
KHR 4032.593576
KMF 414.399915
KPW 899.999067
KRW 1451.42979
KWD 0.30681
KYD 0.833761
KZT 492.246531
LAK 21486.714209
LBP 89522.281894
LKR 309.580141
LRD 186.599091
LSL 15.938326
LTL 2.95274
LVL 0.60489
LYD 6.307756
MAD 9.121259
MDL 16.933027
MGA 4429.297238
MKD 51.751639
MMK 2099.913606
MNT 3568.190929
MOP 8.056446
MRU 39.329271
MUR 45.679749
MVR 15.449836
MWK 1734.822093
MXN 17.214865
MYR 3.914984
MZN 63.898797
NAD 15.938527
NGN 1353.389896
NIO 36.82116
NOK 9.46565
NPR 144.931312
NZD 1.64996
OMR 0.384502
PAB 1.000504
PEN 3.359612
PGK 4.2923
PHP 58.249062
PKR 279.886956
PLN 3.54075
PYG 6585.112687
QAR 3.647007
RON 4.276306
RSD 98.555023
RUB 77.27212
RWF 1460.743567
SAR 3.750472
SBD 8.058149
SCR 13.736914
SDG 601.474628
SEK 8.864502
SGD 1.26252
SHP 0.750259
SLE 24.350262
SLL 20969.499267
SOS 571.774366
SRD 37.889832
STD 20697.981008
STN 20.59161
SVC 8.754376
SYP 11059.574895
SZL 15.922777
THB 31.02969
TJS 9.389882
TMT 3.51
TND 2.882406
TOP 2.40776
TRY 43.643401
TTD 6.786071
TWD 31.410299
TZS 2590.153978
UAH 43.08933
UGX 3556.990006
UYU 38.36876
UZS 12326.389618
VES 384.79041
VND 26000
VUV 119.366255
WST 2.707053
XAF 551.314711
XAG 0.011671
XAU 0.000196
XCD 2.70255
XCG 1.803175
XDR 0.685659
XOF 551.314711
XPF 100.234491
YER 238.325027
ZAR 15.86858
ZMK 9001.197781
ZMW 19.034211
ZWL 321.999592
  • RBGPF

    0.1000

    82.5

    +0.12%

  • RYCEF

    0.5300

    17.41

    +3.04%

  • RIO

    0.3900

    97.24

    +0.4%

  • CMSC

    0.1070

    23.692

    +0.45%

  • SCS

    0.0200

    16.14

    +0.12%

  • NGG

    0.3700

    88.76

    +0.42%

  • AZN

    5.3900

    193.4

    +2.79%

  • RELX

    -0.1900

    29.29

    -0.65%

  • VOD

    -0.2300

    15.25

    -1.51%

  • GSK

    -0.1900

    58.82

    -0.32%

  • BP

    -2.2500

    36.97

    -6.09%

  • BTI

    -0.9600

    60.19

    -1.59%

  • BCC

    0.7100

    89.73

    +0.79%

  • BCE

    0.2100

    25.83

    +0.81%

  • CMSD

    0.1100

    24.08

    +0.46%

  • JRI

    -0.0300

    12.78

    -0.23%

SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks
SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

NEW YORK, NY / ACCESS Newswire / December 19, 2025 / Cannabis is entering a phase where identity matters more than narrative. As federal oversight takes shape, the industry is being pulled out of a patchwork of state systems and into a framework that resembles other regulated categories. In those environments, compliance is not about disclosure. It is about proof.

Text size:

That shift changes what it means to operate at scale.

Federal normalization does not immediately transform cannabis into a pharmaceutical, but it does move it closer to medical-grade expectations. Products that are ingested, absorbed, or used therapeutically are judged by how well their physical reality aligns with their records. Labels, declarations, and after-the-fact reporting are no longer sufficient. Regulators expect continuity between what a product is and what the system says it is.

This is where identity becomes infrastructure. Here's why it's vital to this conversation.

Cannabis Needs Verification, Not Visibility

Most cannabis compliance systems were built for speed and local reporting. They track activity, but they do not always verify integrity. Under light oversight, that distinction is tolerable. Under federal scrutiny, it becomes a liability.

Federal regulators expect records that hold up over time. They expect chain-of-custody continuity from origin through distribution. They expect discrepancies to be explainable without reconstruction. When systems rely on manual reconciliation or fragmented data, those expectations are difficult to meet.

SMX (NASDAQ:SMX) approaches this problem at the material level. Instead of relying solely on databases or documentation, its technology embeds identity directly into physical materials. That identity persists through transformation and movement, allowing records to reflect reality rather than attempt to approximate it.

For cannabis, that approach aligns naturally with the direction of federal oversight. When proof is embedded, compliance becomes continuous instead of episodic.

FDA-Compliant RPET Shows The Model Works

This same logic is already operating inside FDA-regulated markets.

SMX recently demonstrated its molecular marking technology in recycled PET plastics used for food-contact applications, operating within FDA Food Contact Substance regulations under 21 CFR. These rules govern some of the most tightly controlled materials in the supply chain. Any system that functions here must demonstrate stability, safety, and verifiable compliance.

In practice, molecular markers allow recycled material to carry permanent, invisible proof of origin, composition, and regulatory status, even in applications where contamination risk is tightly controlled. This enables recycled plastics to move into categories that were previously closed to them.

That matters for cannabis because the regulatory expectation is similar. When a product interacts with the human body, regulators care less about intent and more about verifiable control. Food-grade rPET provides a real-world demonstration that molecular identity can operate inside strict federal frameworks.

From Cannabis To Plastics, The Compliance Logic Is Shared

Cannabis and rPET are different markets, but they face the same regulatory logic. Both require traceability that survives transformation. Both demand proof that cannot be altered downstream. Both expose the weaknesses of systems built on declarations.

SMX's relevance is not tied to a single product category. It is tied to the need for persistent identity in regulated environments. Whether the material is plant-based or polymer-based, the requirement is the same. Physical goods must be able to prove what they are.

As cannabis moves toward federal standards, that requirement becomes unavoidable.

Identity Becomes The Foundation Of Scale

Markets are no longer rewarding speed alone. They are rewarding control.

SMX's ability to embed identity at the molecular level and to operate within FDA-compliant frameworks positions it at the intersection of regulation and scalability. Cannabis operators moving into federal oversight face the same decision that plastics manufacturers already confront. Patch legacy systems, or adopt infrastructure built for verification.

As oversight tightens, the difference becomes decisive.

Cannabis will not be filtered by enthusiasm or branding. It will be filtered by execution. The companies that can prove integrity across their supply chains will advance. Those who cannot will face compounding friction.

Identity is no longer a feature. It is the foundation.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, forecasts, and assumptions regarding future events involving SMX (NASDAQ: SMX), its technologies, its partnership activities, and its development of molecular marking systems for recycled PET and other materials. Forward looking statements are not historical facts. They involve risks, uncertainties, and factors that may cause actual results to differ materially from those expressed or implied.

Forward looking statements in this editorial include, but are not limited to, expectations regarding the integration of SMX's molecular markers into U.S. recycling markets; the potential for FDA-compliant markers to enable recycled PET to enter food-grade and other regulated applications; the scalability of SMX solutions across diverse global supply chains; anticipated adoption of identity-based verification systems by manufacturers, recyclers, regulators, or brand owners; the potential economic impact of turning recycled plastics into tradeable or monetizable assets; the expected performance of SMX's Plastic Cycle Token or other digital verification instruments; and the belief that molecular-level authentication may influence pricing, compliance, sustainability reporting, or financial strategies used within the plastics sector.

These forward looking statements are also subject to assumptions regarding regulatory developments; market demand for authenticated recycled content; the pace of corporate adoption of traceability technology; global economic conditions; supply chain constraints; evolving environmental policies; and general industry behavior relating to sustainability commitments and recycling mandates. Risks include, but are not limited to, changes in FDA or international regulatory standards; technological challenges in large-scale deployment of molecular markers; competitive innovations from other companies; operational disruptions in recycling or plastics manufacturing; fluctuations in pricing for virgin or recycled plastics; and the broader economic conditions that influence capital investment and industrial activity.

Detailed risk factors are described in SMX's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.

EMAIL: [email protected]

SOURCE: SMX (Security Matters) Public Limited



View the original press release on ACCESS Newswire

S.Rocha--TFWP